Johns Hopkins ABX Guide
Baloxavir
INDICATIONS
FDA
FDA
- Treatment of uncomplicated influenza, ages ≥ 12 years with symptoms < 48 hours.
- Limitations of use: Consideration should be given to susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir because viruses’ changing over time, virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of influenza in individuals at high risk for influenza-related complications
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 15, 2022
Citation
Dzintars, Kate, and Edina Avdic. "Baloxavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir.
Dzintars K, Avdic E. Baloxavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir. Accessed July 21, 2025.
Dzintars, K., & Avdic, E. (2022). Baloxavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir
Dzintars K, Avdic E. Baloxavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2025 July 21]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Baloxavir
ID - 540707
A1 - Dzintars,Kate,Pharm.D., BCPS
AU - Avdic,Edina,Pharm.D.
Y1 - 2022/10/15/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
